MYOM3 and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: Multiple blood-borne molecules that are widely recognised as biomarkers of dystrophin deficiency in human DMD patients were also found to be significantly altered in the serum of DE50-MD dogs compared to WT controls, with peak circulating CK activity and levels of myomesin 3 (MYOM3) and the microRNA dystromiR-206 coinciding with the period of intense degeneration and inflammation observed in muscle samples, between 3 and 9 months of age (Riddell et al., 2021).